- Previous Close
3.3300 - Open
3.6400 - Bid --
- Ask --
- Day's Range
2.9700 - 3.6400 - 52 Week Range
1.9220 - 4.7500 - Volume
60,429 - Avg. Volume
92,067 - Market Cap (intraday)
90.66M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-4.4400 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.25
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
www.oncocyte.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: OCX
View More
Performance Overview: OCX
Trailing total returns as of 3/25/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OCX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OCX
View MoreValuation Measures
Market Cap
95.24M
Enterprise Value
95.86M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
50.65
Price/Book (mrq)
9.81
Enterprise Value/Revenue
135.21
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.42%
Return on Equity (ttm)
-910.86%
Revenue (ttm)
1.88M
Net Income Avi to Common (ttm)
-60.66M
Diluted EPS (ttm)
-4.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
8.64M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-15.94M
Research Analysis: OCX
View MoreCompany Insights: OCX
OCX does not have Company Insights
Research Reports: OCX
View MoreDaily – Vickers Top Buyers & Sellers for 02/13/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/07/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Insider Picks for 09/27/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 09/02/2022
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.